Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05180994
PHASE1/PHASE2

Topical Infliximab in Eyes With Penetrating Keratoplasty

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

View on ClinicalTrials.gov

Summary

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2022-05-01

Completion Date

2028-03-01

Last Updated

2024-08-22

Healthy Volunteers

No

Interventions

DRUG

Topical infliximab

Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

OTHER

No topical infliximab

No treatment with infliximab.

Locations (1)

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada